Clinical Trial

CEB-01 in Locally Resectable Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the pancreatic cancer tumor, CEB 01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of pancreatic cancer after surgery, while keeping a tolerable toxicity profile. The study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in patients with locally resectable pancreatic cancer
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-08-05; most recent amendment 2025-05-20.
Trial Details
NCT Number NCT06538857
Lead Sponsor CEBIOTEX
Collaborators: MFAR
Conditions Pancreatic Carcinoma
Enrollment 39 participants
Start Date 2024-08-20
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2025-05-23